APAC Non-Hodgkin Lymphoma Diagnostics Market - Industry Trends and Forecast to 2030

Description

List of Tables

The Asia-Pacific non-Hodgkin lymphoma diagnostics market is projected to register a substantial CAGR of 8.4% in the forecast period of 2023 to 2030. The new market report contains data for the historic year 2021, the base year of calculation is 2022, and the forecast period is 2023 to 2030.

Market Segmentation:

Asia-Pacific Non-Hodgkin Lymphoma Diagnostics Market, By Test Type (Imaging, Biopsy, Immunohistochemistry, Biomarker Test, Genetic Test, Cytogenetics, Lumbar Puncture (Spinal Tap), Blood Test and Cytochemistry), Cancer Stage (Stage IV, Stage III, Stage II, Stage I, and Stage 0), Tumor Type (Aggressive Lymphomas and Indolent Lymphomas), Product (Instrument Based Products, Platform Based Products, Kits and Reagents, and Other Consumables), Technology (Fluorescent In Situ Hybridization, Next Generation Sequencing, Fluorimmunoassay, Comparative Genomic Hybridization, Immunohistochemical and Others), Application (Screening, Diagnostic and Predictive, Prognostic, and Research), End User (Hospitals, Diagnostic Centers, Cancer Research Centers, Academic Institutes, Ambulatory Surgical Centers, and Others), Distribution Channel (Direct Tender, Retail Sales, and Others), Country (Japan, China, South Korea, India, Australia, Singapore, Thailand, Malaysia, Indonesia, Philippines, Rest of Asia-Pacific) Industry Trends and Forecast to 2030.

Some of the major factors contributing to the growth of Asia-Pacific non-Hodgkin lymphoma diagnostics market are:

Increased growth in the prevalence of non-Hodgkin lymphoma

Advancement in artificial intelligence in the diagnosis of non-Hodgkin lymphoma

Market Players:

Some of the major players operating in the Asia-Pacific Non-Hodgkin lymphoma diagnostics market are:

CANON MEDICAL SYSTEMS CORPORATION

Koninklijke Philips N.V.

Siemens Healthcare GmbH

Danaher.

Bio-Rad Laboratories, Inc.

General Electric Company

Sysmex Corporation

Grail

F. Hoffmann-La Roche

Neusoft Corporation

Agilent Technologies, Inc.

NeoGenomics Laboratories

Hologic, Inc

Integrated DNA Technologies, Inc.

CENTOGENE N.V.

Merit Medical Systems

Invitae Corporation

PerkinElmer Inc.

QIAGEN

GeneDx, LLC

1 INTRODUCTION 84

1.1 OBJECTIVES OF THE STUDY 84
1.2 MARKET DEFINITION 84
1.3 OVERVIEW OF THE ASIA PACIFIC NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET 84
1.4 LIMITATIONS 86
1.5 MARKETS COVERED 87

2 MARKET SEGMENTATION 90

2.1 MARKETS COVERED 90
2.2 GEOGRAPHICAL SCOPE 91
2.3 YEARS CONSIDERED FOR THE STUDY 92
2.4 CURRENCY AND PRICING 92
2.5 DBMR TRIPOD DATA VALIDATION MODEL 93
2.6 MULTIVARIATE MODELLING 96
2.7 PRODUCT TYPE LIFELINE CURVE 96
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 97
2.9 DBMR MARKET POSITION GRID 98
2.10 MARKET APPLICATION COVERAGE GRID 99
2.11 VENDOR SHARE ANALYSIS 100
2.12 SECONDARY SOURCES 101
2.13 ASSUMPTIONS 101

3 EXECUTIVE SUMMARY 102

4 PREMIUM INSIGHTS 105

4.1 PESTEL ANALYSIS 106
4.2 PORTER'S 5 FORCES 107

5 INDUSTRY INSIGHTS 108

6 ASIA PACIFIC NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, REGULATIONS 109

7 MARKET OVERVIEW 111

7.1 DRIVERS 113
- 7.1.1 INCREASED GROWTH IN PREVALENCE OF NON-HODGKIN LYMPHOMA 113
- 7.1.2 INCREASE IN AWARENESS REGARDING NON-HODGKIN LYMPHOMA 113
- 7.1.3 ADVANCEMENT IN ARTIFICIAL INTELLIGENCE IN DIAGNOSIS OF NON-HODGKIN LYMPHOMA 113
- 7.1.4 RISING PREFERENCE FOR PREVENTIVE HEALTH CHECK-UP 114
7.2 RESTRAINTS 114
- 7.2.1 LACK OF AVAILABILITY OF TRAINED AND SKILLED MEDICAL PROFESSIONALS 114
- 7.2.2 STRINGENT REGULATIONS AND GUIDELINES FOR DIFFERENT TREATMENTS AND DIAGNOSIS 115
7.3 OPPORTUNITIES 116
- 7.3.1 TECHNICAL ADVANCEMENTS IN CANCER DIAGNOSIS 116
- 7.3.2 INCREASING HEALTHCARE EXPENDITURE IN CANCER R&D 116
- 7.3.3 GROWING INITIATIVES BY GOVERNMENT AND KEY PLAYERS 116
7.4 CHALLENGES 117
- 7.4.1 LACK OF EARLY DIAGNOSTIC AWARENESS AMONG PEOPLE 117
- 7.4.2 HIGH DIAGNOSTIC COST AND FEAR OF TREATMENT 117
- 7.4.3 COMMON MISDIAGNOSIS OF NON-HODGKIN LYMPHOMA (NHL) 118

8 ASIA PACIFIC NON-HODGKIN LYMPHOMA DIAGNOSTIC MARKET, BY TEST TYPE 119

8.1 OVERVIEW 120
8.2 IMAGING 123
- 8.2.1 COMPUTED TOMOGRAPHY (CT) 124
- 8.2.2 CHEST X-RAY 124
- 8.2.3 MAGNETIC RESONANCE IMAGING (MRI) 124
- 8.2.4 ULTRASOUND 124
- 8.2.5 POSITRON EMISSION TOMOGRAPHY (PET) 124
8.3 BIOPSY 124
- 8.3.1 EXCISIONAL OR INCISIONAL BIOPSY 125
- 8.3.2 CORE NEEDLE BIOPSY 125
8.4 IMMUNOHISTOCHEMISTRY 125
8.5 BIOMARKER TEST 126
- 8.5.1 BETA 2-M 127
- 8.5.2 LDH 127
- 8.5.3 CA-125 127
- 8.5.4 TP53 127
- 8.5.5 NPM1 128
- 8.5.6 OTHERS 128
8.6 GENETIC TEST 128
8.7 CYTOGENETICS 128
8.8 LUMBAR PUNCTURE (SPINAL TAP) 129
8.9 BLOOD TEST 130
8.10 CYTOCHEMISTRY 130
8.11 OTHERS 131

9 ASIA PACIFIC NON-HODGKIN LYMPHOMA DIAGNOSTIC MARKET, BY TUMOR TYPE 132

9.1 OVERVIEW 133
9.2 AGGRESSIVE LYMPHOMAS 135
- 9.2.1 DIFFUSE LARGE B CELL LYMPHOMA 136
  - 9.2.1.1 INSTRUMENT BASED PRODUCTS 137
  - 9.2.1.2 PLATFORM BASED PRODUCTS 137
  - 9.2.1.3 KITS AND REAGENTS 137
  - 9.2.1.4 OTHER CONSUMABLES 137
- 9.2.2 ANAPLASTIC LARGE-CELL LYMPHOMA 137
  - 9.2.2.1 INSTRUMENT BASED PRODUCTS 138
  - 9.2.2.2 PLATFORM BASED PRODUCTS 138
  - 9.2.2.3 KITS AND REAGENTS 138
  - 9.2.2.4 OTHER CONSUMABLES 138
- 9.2.3 MANTLE CELL LYMPHOMA 138
  - 9.2.3.1 INSTRUMENT BASED PRODUCTS 139
  - 9.2.3.2 PLATFORM BASED PRODUCTS 139
  - 9.2.3.3 KITS AND REAGENTS 139
  - 9.2.3.4 OTHER CONSUMABLES 139
- 9.2.4 PERIPHERAL T-CELL LYMPHOMA 139
  - 9.2.4.1 INSTRUMENT BASED PRODUCTS 140
  - 9.2.4.2 PLATFORM BASED PRODUCTS 140
  - 9.2.4.3 KITS AND REAGENTS 140
  - 9.2.4.4 OTHER CONSUMABLES 140
- 9.2.5 LYMPHOBLASTIC LYMPHOMA 140
  - 9.2.5.1 INSTRUMENT BASED PRODUCTS 141
  - 9.2.5.2 PLATFORM BASED PRODUCTS 141
  - 9.2.5.3 KITS AND REAGENTS 141
  - 9.2.5.4 OTHER CONSUMABLES 141
- 9.2.6 BURKITT LYMPHOMA 141
  - 9.2.6.1 INSTRUMENT BASED PRODUCTS 142
  - 9.2.6.2 PLATFORM BASED PRODUCTS 142
  - 9.2.6.3 KITS AND REAGENTS 142
  - 9.2.6.4 OTHER CONSUMABLES 142
9.3 INDOLENT LYMPHOMAS 142
- 9.3.1 FOLLICULAR LYMPHOMA 143
  - 9.3.1.1 INSTRUMENT BASED PRODUCTS 144
  - 9.3.1.2 PLATFORM BASED PRODUCTS 144
  - 9.3.1.3 KITS AND REAGENTS 144
  - 9.3.1.4 OTHER CONSUMABLES 144
- 9.3.2 CUTANEOUS T-CELL LYMPHOMA 144
  - 9.3.2.1 INSTRUMENT BASED PRODUCTS 145
  - 9.3.2.2 PLATFORM BASED PRODUCTS 145
  - 9.3.2.3 KITS AND REAGENTS 145
  - 9.3.2.4 OTHER CONSUMABLES 145
- 9.3.3 MARGINAL ZONE B CELL LYMPHOMA 145
  - 9.3.3.1 INSTRUMENT BASED PRODUCTS 146
  - 9.3.3.2 PLATFORM BASED PRODUCTS 146
  - 9.3.3.3 KITS AND REAGENTS 146
  - 9.3.3.4 OTHER CONSUMABLES 146
- 9.3.4 LYMPHOPLASMACYTIC LYMPHOMA 146
  - 9.3.4.1 INSTRUMENT BASED PRODUCTS 147
  - 9.3.4.2 PLATFORM BASED PRODUCTS 147
  - 9.3.4.3 KITS AND REAGENTS 147
  - 9.3.4.4 OTHER CONSUMABLES 147
- 9.3.5 SMALL-CELL LYMPHOCYTIC LYMPHOMA 147
  - 9.3.5.1 INSTRUMENT BASED PRODUCTS 148
  - 9.3.5.2 PLATFORM BASED PRODUCTS 148
  - 9.3.5.3 KITS AND REAGENTS 148
  - 9.3.5.4 OTHER CONSUMABLES 148

10 ASIA PACIFIC NON-HODGKIN LYMPHOMA DIAGNOSTIC MARKET, BY APPLICATION 149

10.1 OVERVIEW 150
10.2 SCREENING 152
- 10.2.1 INSTRUMENT BASED PRODUCTS 153
- 10.2.2 PLATFORM BASED PRODUCTS 153
- 10.2.3 KITS AND REAGENTS 154
- 10.2.4 OTHER CONSUMABLES 154
10.3 DIAGNOSTIC AND PREDICTIVE 154
- 10.3.1 INSTRUMENT BASED PRODUCTS 155
- 10.3.2 PLATFORM BASED PRODUCTS 155
- 10.3.3 KITS AND REAGENTS 155
- 10.3.4 OTHER CONSUMABLES 155
10.4 PROGNOSTIC 155
- 10.4.1 INSTRUMENT BASED PRODUCTS 156
- 10.4.2 PLATFORM BASED PRODUCTS 156
- 10.4.3 KITS AND REAGENTS 156
- 10.4.4 OTHER CONSUMABLES 157
10.5 RESEARCH 157
- 10.5.1 INSTRUMENT BASED PRODUCTS 158
- 10.5.2 PLATFORM BASED PRODUCTS 158
- 10.5.3 KITS AND REAGENTS 158
- 10.5.4 OTHER CONSUMABLES 158

11 ASIA PACIFIC NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY CANCER STAGE 159

11.1 OVERVIEW 160
11.2 STAGE IV 162
11.3 STAGE I 163
11.4 STAGE III 164
11.5 STAGE II 165
11.6 STAGE 0 166

12 ASIA PACIFIC NON-HODGKIN LYMPHOMA DIAGNOSTIC MARKET, BY TECHNOLOGY 167

12.1 OVERVIEW 168
12.2 FLUORESCENT IN SITU HYBRIDIZATION 170
12.3 NEXT GENERATION SEQUENCING 171
12.4 FLUORIMMUNOASSAY 172
12.5 COMPARATIVE GENOMIC HYBRIDIZATION 173
12.6 IMMUNOHISTOLOCHEMICAL 173
12.7 OTHER 174

13 ASIA PACIFIC NON-HODGKIN LYMPHOMA DIAGNOSTIC MARKET, BY PRODUCT 175

13.1 OVERVIEW 176
13.2 INSTRUMENT BASED PRODUCTS 178
- 13.2.1 IMAGING 179
- 13.2.2 BIOPSY 179
13.3 PLATFORM BASED PRODUCTS 180
- 13.3.1 NEXT-GENERATION SEQUENCING 181
- 13.3.2 MICROARRAYS 181
- 13.3.3 PCR 181
- 13.3.4 OTHERS 181
13.4 KITS AND REAGENTS 181
- 13.4.1 NON-HODGKIN LYMPHOMA PANELS 182
- 13.4.2 IMMUNOHISTOCHEMISTRY STAINS 182
- 13.4.3 OTHERS 182
13.5 OTHER CONSUMABLES 183

14 ASIA PACIFIC NON-HODGKIN LYMPHOMA DIAGNOSTIC MARKET, BY END USER 184

14.1 OVERVIEW 185
14.2 HOSPITALS 187
14.3 DIAGNOSTIC CENTERS 188
14.4 CANCER RESEARCH CENTERS 189
14.5 ACADEMIC INSTITUTES 190
14.6 AMBULATORY SURGICAL CENTERS 190
14.7 OTHERS 191

15 ASIA PACIFIC NON-HODGKIN LYMPHOMA DIAGNOSTIC MARKET, BY DISTRIBUTION CHANNEL 192

15.1 OVERVIEW 193
15.2 DIRECT TENDER 195
15.3 RETAIL SALES 196
15.4 OTHERS 197

16 ASIA PACIFIC NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION 198

16.1 ASIA-PACIFIC 199
- 16.1.1 CHINA 219
- 16.1.2 JAPAN 233
- 16.1.3 INDIA 247
- 16.1.4 AUSTRALIA 261
- 16.1.5 SOUTH KOREA 275
- 16.1.6 INDONESIA 289
- 16.1.7 PHILIPPINES 303
- 16.1.8 THAILAND 317
- 16.1.9 MALAYSIA 331
- 16.1.10 VIETNAM 345
- 16.1.11 SINGAPORE 358
- 16.1.12 REST OF ASIA-PACIFIC 372

17 ASIA PACIFIC NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET: COMPANY LANDSCAPE 373

17.1 COMPANY SHARE ANALYSIS: ASIA PACIFIC 373

18 SWOT ANALYSIS 374

19 ASIA PACIFIC NON-HODKIN LYMPHOMA DIAGNOSTICS MARKET 375

19.1 CANON MEDICAL SYSTEMS CORPORATION 375
- 19.1.1 COMPANY SNAPSHOT 375
- 19.1.2 REVENUE ANALYSIS 375
- 19.1.3 COMPANY SHARE ANALYSIS 376
- 19.1.4 PRODUCT PORTFOLIO 376
- 19.1.5 RECENT DEVELOPMENT 376
19.2 KONINKLIJKE PHILIPS N.V. 377
- 19.2.1 COMPANY SNAPSHOT 377
- 19.2.2 REVENUE ANALYSIS 377
- 19.2.3 COMPANY SHARE ANALYSIS 378
- 19.2.4 PRODUCT PORTFOLIO 378
- 19.2.5 RECENT DEVELOPMENTS 378
19.3 SIEMENS HEALTHCARE GMBH 379
- 19.3.1 COMPANY SNAPSHOT 379
- 19.3.2 REVENUE ANALYSIS 379
- 19.3.3 COMPANY SHARE ANALYSIS 380
- 19.3.4 PRODUCT PORTFOLIO 380
- 19.3.5 RECENT DEVELOPMENT 381
19.4 DANAHER. 382
- 19.4.1 COMPANY SNAPSHOT 382
- 19.4.2 REVENUE ANALYSIS 382
- 19.4.3 COMPANY SHARE ANALYSIS 383
- 19.4.4 PRODUCT PORTFOLIO 383
- 19.4.5 RECENT DEVELOPMENTS 384
19.5 BIO-RAD LABORATORIES, INC. 385
- 19.5.1 COMPANY SNAPSHOT 385
- 19.5.2 REVENUE ANALYSIS 385
- 19.5.3 COMPANY SHARE ANALYSIS 386
- 19.5.4 PRODUCT PORTFOLIO 386
- 19.5.5 RECENT DEVELOPMENT 386
19.6 AGILENT TECHNOLOGIES, INC. 387
- 19.6.1 COMPANY PROFILE 387
- 19.6.2 REVENUE ANALYSIS 387
- 19.6.3 PRODUCT PORTFOLIO 388
- 19.6.4 RECENT DEVELOPMENT 388
19.7 CENTOGENE N.V. 389
- 19.7.1 COMPANY SNAPSHOT 389
- 19.7.2 PRODUCT PORTFOLIO 389
- 19.7.3 RECENT DEVELOPMENT 389

19.8 F. HOFFMANN- LA ROCHE LTD 390
- 19.8.1 COMPANY SNAPSHOT 390
- 19.8.2 REVENUE ANALYSIS 390
- 19.8.3 PRODUCT PORTFOLIO 391
- 19.8.4 RECENT DEVELOPMENTS 391
19.9 GENERAL ELECTRIC COMPANY 392
- 19.9.1 COMPANY SNAPSHOT 392
- 19.9.2 REVENUE ANALYSIS 392
- 19.9.3 PRODUCT PORTFOLIO 393
- 19.9.4 RECENT DEVELOPMENTS 393
19.10 GENEDX, LLC 394
- 19.10.1 COMPANY SNAPSHOT 394
- 19.10.2 PRODUCT PORTFOLIO 394
- 19.10.3 RECENT DEVELOPMENT 394
19.11 GRAIL 395
- 19.11.1 COMPANY PROFILE 395
- 19.11.2 PRODUCT PORTFOLIO 395
- 19.11.3 RECENT DEVELOPMENT 395
19.12 HOLOGIC INC. 396
- 19.12.1 COMPANY SNAPSHOT 396
- 19.12.2 REVENUE ANALYSIS 396
- 19.12.3 PRODUCT PORTFOLIO 397
- 19.12.4 RECENT DEVELOPMENT 397
19.13 INVITAE CORPORATION 398
- 19.13.1 COMPANY PROFILE 398
- 19.13.2 REVENUE ANALYSIS 398
- 19.13.3 PRODUCT PORTFOLIO 399
- 19.13.4 RECENT DEVELOPMENT 399
19.14 NEUSOFT CORPORATION 400
- 19.14.1 COMPANY SNAPSHOT 400
- 19.14.2 REVENUE ANALYSIS 400
- 19.14.3 PRODUCT PORTFOLIO 401
- 19.14.4 RECENT DEVELOPMENT 401
19.15 NEOGENOMICS LABORATORIES 402
- 19.15.1 COMPANY SNAPSHOT 402
- 19.15.2 REVENUE ANALYSIS 402
- 19.15.3 PRODUCT PORTFOLIO 403
- 19.15.4 RECENT DEVELOPMENTS 403
19.16 PERKINELMER INC 404
- 19.16.1 COMPANY PROFILE 404
- 19.16.2 REVENUE ANALYSIS 404
- 19.16.3 PRODUCT PORTFOLIO 405
- 19.16.4 RECENT DEVELOPMENT 405
19.17 QIAGEN 406
- 19.17.1 COMPANY SNAPSHOT 406
- 19.17.2 REVENUE ANALYSIS 406
- 19.17.3 PRODUCT PORTFOLIO 407
- 19.17.4 RECENT DEVELOPMENT 407
19.18 SYSMEX CORPORATION 408
- 19.18.1 COMPANY SNAPSHOT 408
- 19.18.2 REVENUE ANALYSIS 408
- 19.18.3 PRODUCT PORTFOLIO 409
- 19.18.4 RECENT DEVELOPMENTS 409

20 QUESTIONNAIRE 410

21 RELATED REPORTS 414

LIST OF TABLES

TABLE 1 ASIA PACIFIC NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 79
TABLE 2 ASIA PACIFIC IMAGING IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 80
TABLE 3 ASIA PACIFIC IMAGING IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 80
TABLE 4 ASIA PACIFIC BIOPSY IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 82
TABLE 5 ASIA PACIFIC BIOPSY IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 82
TABLE 6 ASIA PACIFIC IMMUNOHISTOCHEMISTRY IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 83
TABLE 7 ASIA PACIFIC BIOMARKER TEST IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 84
TABLE 8 ASIA PACIFIC BIOMARKER TEST IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 84
TABLE 9 ASIA PACIFIC GENETIC TEST IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 85
TABLE 10 ASIA PACIFIC CYTOGENETICS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 86
TABLE 11 ASIA PACIFIC LUMBAR PUNCTURE (SPINAL TAP) IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 86
TABLE 12 ASIA PACIFIC BLOOD TEST IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 87
TABLE 13 ASIA PACIFIC CYTOCHEMISTRY IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 88
TABLE 14 ASIA PACIFIC OTHERS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 88
TABLE 15 ASIA PACIFIC NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION) 92
TABLE 16 ASIA PACIFIC AGGRESSIVE LYMPHOMAS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 93
TABLE 17 ASIA PACIFIC AGGRESSIVE LYMPHOMAS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION) 93
TABLE 18 ASIA PACIFIC DIFFUSE LARGE B CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 94
TABLE 19 ASIA PACIFIC ANAPLASTIC LARGE-CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 95
TABLE 20 ASIA PACIFIC MANTLE CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 96
TABLE 21 ASIA PACIFIC PERIPHERAL T-CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 97
TABLE 22 ASIA PACIFIC LYMPHOBLASTIC LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 98
TABLE 23 ASIA PACIFIC BURKITT LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 99
TABLE 24 ASIA PACIFIC INDOLENT LYMPHOMAS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 100
TABLE 25 ASIA PACIFIC AGGRESSIVE LYMPHOMAS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION) 100
TABLE 26 ASIA PACIFIC FOLLICULAR LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 101
TABLE 27 ASIA PACIFIC CUTANEOUS T-CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 102
TABLE 28 ASIA PACIFIC MARGINAL ZONE B CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 103
TABLE 29 ASIA PACIFIC LYMPHOPLASMACYTIC LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 104
TABLE 30 ASIA PACIFIC SMALL-CELL LYMPHOCYTIC LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 105
TABLE 31 ASIA PACIFIC NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 109
TABLE 32 ASIA PACIFIC SCREENING IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 110
TABLE 33 ASIA PACIFIC SCREENING IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 110
TABLE 34 ASIA PACIFIC DIAGNOSTIC AND PREDICTIVE IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 111
TABLE 35 ASIA PACIFIC DIAGNOSTIC AND PREDICTIVE IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 112
TABLE 36 ASIA PACIFIC PROGNOSTIC IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 113
TABLE 37 ASIA PACIFIC PROGNOSTIC IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 113
TABLE 38 ASIA PACIFIC RESEARCH IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 114
TABLE 39 ASIA PACIFIC RESEARCH IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 115
TABLE 40 ASIA PACIFIC NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION) 119
TABLE 41 ASIA PACIFIC STAGE IV IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 120
TABLE 42 ASIA PACIFIC STAGE I IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 121
TABLE 43 ASIA PACIFIC STAGE III IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 122
TABLE 44 ASIA PACIFIC STAGE II IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION 122
TABLE 45 ASIA PACIFIC STAGE 0 IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 123
TABLE 46 ASIA PACIFIC NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION) 127
TABLE 47 ASIA PACIFIC FLUORESCENT IN SITU HYBRIDIZATION IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 128
TABLE 48 ASIA PACIFIC NEXT GENERATION SEQUENCING IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 129
TABLE 49 ASIA PACIFIC FLUORIMMUNOASSAY IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 129
TABLE 50 ASIA PACIFIC COMPARATIVE GENOMIC HYBRIDIZATION IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 130
TABLE 51 ASIA PACIFIC IMMUNOHISTOCHEMICAL IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 131
TABLE 52 ASIA PACIFIC OTHERS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 131
TABLE 53 ASIA PACIFIC NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 135
TABLE 54 ASIA PACIFIC INSTRUMENT BASED PRODUCTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 136
TABLE 55 ASIA PACIFIC INSTRUMENT BASED PRODUCTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 136
TABLE 56 ASIA PACIFIC PLATFORM BASED PRODUCTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 137
TABLE 57 ASIA PACIFIC PLATFORM BASED PRODUCTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 138
TABLE 58 ASIA PACIFIC KITS AND REAGENTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 139
TABLE 59 ASIA PACIFIC INSTRUMENT BASED PRODUCTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 139
TABLE 60 ASIA PACIFIC OTHER CONSUMABLES IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)) 140
TABLE 61 ASIA PACIFIC NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION) 144
TABLE 62 ASIA PACIFIC HOSPITALS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 145
TABLE 63 ASIA PACIFIC DIAGNOSTIC CENTERS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 146
TABLE 64 ASIA PACIFIC CANCER RESEARCH CENTERS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 146
TABLE 65 ASIA PACIFIC ACADEMIC INSTITUTES IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 147
TABLE 66 ASIA PACIFIC AMBULATORY SURGICAL CENTERS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 148
TABLE 67 ASIA PACIFIC OTHERS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 148
TABLE 68 ASIA PACIFIC NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 152
TABLE 69 ASIA PACIFIC DIRECT TENDER IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 153
TABLE 70 ASIA PACIFIC RETAIL SALES IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 153
TABLE 71 ASIA PACIFIC OTHERS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 154
TABLE 72 ASIA-PACIFIC NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY COUNTRY, 2021-2030 (USD MILLION) 162
TABLE 73 ASIA-PACIFIC NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 162
TABLE 74 ASIA-PACIFIC IMAGING IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 163
TABLE 75 ASIA-PACIFIC BIOPSY IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 163
TABLE 76 ASIA-PACIFIC BIOMARKER TEST IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 163
TABLE 77 ASIA-PACIFIC NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION) 164
TABLE 78 ASIA-PACIFIC NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION) 164
TABLE 79 ASIA-PACIFIC AGGRESSIVE LYMPHOMAS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION) 164
TABLE 80 ASIA-PACIFIC DIFFUSE LARGE B CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 165
TABLE 81 ASIA-PACIFIC ANAPLASTIC LARGE-CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 165
TABLE 82 ASIA-PACIFIC MANTLE CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 165
TABLE 83 ASIA-PACIFIC PERIPHERAL T-CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 166
TABLE 84 ASIA-PACIFIC LYMPHOBLASTIC LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 166
TABLE 85 ASIA-PACIFIC BURKITT LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 166
TABLE 86 ASIA-PACIFIC INDOLENT LYMPHOMAS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION) 167
TABLE 87 ASIA-PACIFIC FOLLICULAR LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 167
TABLE 88 ASIA-PACIFIC CUTANEOUS T-CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 167
TABLE 89 ASIA-PACIFIC MARGINAL ZONE B CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 168
TABLE 90 ASIA-PACIFIC LYMPHOPLASMACYTIC LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 168
TABLE 91 ASIA-PACIFIC SMALL-CELL LYMPHOCYTIC LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 168
TABLE 92 ASIA-PACIFIC NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 169
TABLE 93 ASIA-PACIFIC INSTRUMENT BASED PRODUCTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 169
TABLE 94 ASIA-PACIFIC INSTRUMENT BASED PRODUCTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS) 169
TABLE 95 ASIA-PACIFIC INSTRUMENT BASED PRODUCTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD) 169
TABLE 96 ASIA-PACIFIC PLATFORM BASED PRODUCTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 170
TABLE 97 ASIA-PACIFIC PLATFORM BASED PRODUCTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS) 170
TABLE 98 ASIA-PACIFIC PLATFORM BASED PRODUCTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD) 170
TABLE 99 ASIA-PACIFIC KITS AND REAGENTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 171
TABLE 100 ASIA-PACIFIC KITS AND REAGENTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS) 171
TABLE 101 ASIA-PACIFIC KITS AND REAGENTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD) 171
TABLE 102 ASIA-PACIFIC NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION) 172
TABLE 103 ASIA-PACIFIC NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 172
TABLE 104 ASIA-PACIFIC SCREENING IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 173
TABLE 105 ASIA-PACIFIC DIAGNOSTIC AND PREDICTIVE IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 173
TABLE 106 ASIA-PACIFIC PROGNOSTIC IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 173
TABLE 107 ASIA-PACIFIC RESEARCH IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 174
TABLE 108 ASIA-PACIFIC NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION) 174
TABLE 109 ASIA-PACIFIC NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 175
TABLE 110 CHINA NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 176
TABLE 111 CHINA IMAGING IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 177
TABLE 112 CHINA BIOPSY IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 177
TABLE 113 CHINA BIOMARKER TEST IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 177
TABLE 114 CHINA NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION) 178
TABLE 115 CHINA NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION) 178
TABLE 116 CHINA AGGRESSIVE LYMPHOMAS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION) 178
TABLE 117 CHINA DIFFUSE LARGE B CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 179
TABLE 118 CHINA ANAPLASTIC LARGE-CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 179
TABLE 119 CHINA MANTLE CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 179
TABLE 120 CHINA PERIPHERAL T-CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 180
TABLE 121 CHINA LYMPHOBLASTIC LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 180
TABLE 122 CHINA BURKITT LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 180
TABLE 123 CHINA INDOLENT LYMPHOMAS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION) 181
TABLE 124 CHINA FOLLICULAR LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 181
TABLE 125 CHINA CUTANEOUS T-CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 182
TABLE 126 CHINA MARGINAL ZONE B CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 182
TABLE 127 CHINA LYMPHOPLASMACYTIC LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 182
TABLE 128 CHINA SMALL-CELL LYMPHOCYTIC LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 183
TABLE 129 CHINA NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 183
TABLE 130 CHINA INSTRUMENT BASED PRODUCTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 183
TABLE 131 CHINA INSTRUMENT BASED PRODUCTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS) 184
TABLE 132 CHINA INSTRUMENT BASED PRODUCTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD) 184
TABLE 133 CHINA PLATFORM BASED PRODUCTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 184
TABLE 134 CHINA PLATFORM BASED PRODUCTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS) 184
TABLE 135 CHINA PLATFORM BASED PRODUCTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD) 185
TABLE 136 CHINA KITS AND REAGENTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 185

LIST OF FIGURES

FIGURE 1 ASIA PACIFIC NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET: SEGMENTATION 46
FIGURE 2 ASIA PACIFIC NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET: DATA TRIANGULATION 49
FIGURE 3 ASIA PACIFIC NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET: DROC ANALYSIS 50
FIGURE 4 ASIA PACIFIC NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET: ASIA PACIFIC VS REGIONAL MARKET ANALYSIS 51
FIGURE 5 ASIA PACIFIC NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET: COMPANY RESEARCH ANALYSIS 51
FIGURE 6 ASIA PACIFIC NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET: MULTIVARIATE MODELLING 52
FIGURE 7 ASIA PACIFIC NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET: INTERVIEW DEMOGRAPHICS 53
FIGURE 8 ASIA PACIFIC NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET: DBMR MARKET POSITION GRID 54
FIGURE 9 ASIA PACIFIC NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET: MARKET APPLICATION COVERAGE GRID 55
FIGURE 10 ASIA PACIFIC NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET: VENDOR SHARE ANALYSIS 56
FIGURE 11 ASIA PACIFIC NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET: SEGMENTATION 60
FIGURE 12 THE INCREASING PREVALENCE OF NON-HODGKIN LYMPHOMA AND INCREASED RESEARCH & DEVELOPMENT IN NON-HODGKIN LYMPHOMA DIAGNOSTICS ARE DRIVING THE ASIA PACIFIC NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET IN THE FORECAST PERIOD OF 2023 TO 2030 61
FIGURE 13 REAGENTS & CONSUMABLES SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE ASIA PACIFIC NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET IN 2021 & 2028 61
FIGURE 14 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE ASIA PACIFIC NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET 68
FIGURE 15 ASIA PACIFIC NON-HODGKIN LYMPHOMA DIAGNOSTIC MARKET: BY TEST TYPE, 2022 76
FIGURE 16 ASIA PACIFIC NON-HODGKIN LYMPHOMA DIAGNOSTIC MARKET: BY TEST TYPE, 2023-2030 (USD MILLION) 77
FIGURE 17 ASIA PACIFIC NON-HODGKIN LYMPHOMA DIAGNOSTIC MARKET: BY TEST TYPE, CAGR (2023-2030) 77
FIGURE 18 ASIA PACIFIC NON-HODGKIN LYMPHOMA DIAGNOSTIC MARKET: BY TEST TYPE, LIFELINE CURVE 78
FIGURE 19 ASIA PACIFIC NON-HODGKIN LYMPHOMA DIAGNOSTIC MARKET: BY TUMOR TYPE, 2022 89
FIGURE 20 ASIA PACIFIC NON-HODGKIN LYMPHOMA DIAGNOSTIC MARKET: BY TUMOR TYPE, 2023-2030 (USD MILLION) 90
FIGURE 21 ASIA PACIFIC NON-HODGKIN LYMPHOMA DIAGNOSTIC MARKET: BY TUMOR TYPE, CAGR (2023-2030) 90
FIGURE 22 ASIA PACIFIC NON-HODGKIN LYMPHOMA DIAGNOSTIC MARKET: BY TUMOR TYPE, LIFELINE CURVE 91
FIGURE 23 ASIA PACIFIC NON-HODGKIN LYMPHOMA DIAGNOSTIC MARKET: BY APPLICATION, 2022 106
FIGURE 24 ASIA PACIFIC NON-HODGKIN LYMPHOMA DIAGNOSTIC MARKET: BY APPLICATION, 2023-2030 (USD MILLION) 107
FIGURE 25 ASIA PACIFIC NON-HODGKIN LYMPHOMA DIAGNOSTIC MARKET: BY APPLICATION, CAGR (2023-2030) 107
FIGURE 26 ASIA PACIFIC NON-HODGKIN LYMPHOMA DIAGNOSTIC MARKET: BY APPLICATION, LIFELINE CURVE 108
FIGURE 27 ASIA PACIFIC NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET: BY CANCER STAGE, 2022 116
FIGURE 28 ASIA PACIFIC NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET: BY CANCER STAGE, 2023-2030 (USD MILLION) 117
FIGURE 29 ASIA PACIFIC NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET: BY CANCER STAGE, CAGR (2023-2030) 117
FIGURE 30 ASIA PACIFIC NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET: BY CANCER STAGE, LIFELINE CURVE 118
FIGURE 31 ASIA PACIFIC NON-HODGKIN LYMPHOMA DIAGNOSTIC MARKET: BY TECHNOLOGY, 2022 124
FIGURE 32 ASIA PACIFIC NON-HODGKIN LYMPHOMA DIAGNOSTIC MARKET: BY TECHNOLOGY, 2023-2030 (USD MILLION) 125
FIGURE 33 ASIA PACIFIC NON-HODGKIN LYMPHOMA DIAGNOSTIC MARKET: BY TECHNOLOGY, CAGR (2023-2030) 125
FIGURE 34 ASIA PACIFIC NON-HODGKIN LYMPHOMA DIAGNOSTIC MARKET: BY TECHNOLOGY, LIFELINE CURVE 126
FIGURE 35 ASIA PACIFIC NON-HODGKIN LYMPHOMA DIAGNOSTIC MARKET: BY PRODUCT, 2022 132
FIGURE 36 ASIA PACIFIC NON-HODGKIN LYMPHOMA DIAGNOSTIC MARKET: BY PRODUCT, 2023-2030 (USD MILLION) 133
FIGURE 37 ASIA PACIFIC NON-HODGKIN LYMPHOMA DIAGNOSTIC MARKET: BY PRODUCT, CAGR (2023-2030) 133
FIGURE 38 ASIA PACIFIC NON-HODGKIN LYMPHOMA DIAGNOSTIC MARKET: BY PRODUCT, LIFELINE CURVE 134
FIGURE 39 ASIA PACIFIC NON-HODGKIN LYMPHOMA DIAGNOSTIC MARKET: BY END USER, 2022 141
FIGURE 40 ASIA PACIFIC NON-HODGKIN LYMPHOMA DIAGNOSTIC MARKET: BY END USER, 2023-2030 (USD MILLION) 142
FIGURE 41 ASIA PACIFIC NON-HODGKIN LYMPHOMA DIAGNOSTIC MARKET: BY END USER, CAGR (2023-2030) 142
FIGURE 42 ASIA PACIFIC NON-HODGKIN LYMPHOMA DIAGNOSTIC MARKET: BY END USER, LIFELINE CURVE 143
FIGURE 43 ASIA PACIFIC NON-HODGKIN LYMPHOMA DIAGNOSTIC MARKET: BY DISTRIBUTION CHANNEL, 2022 149
FIGURE 44 ASIA PACIFIC NON-HODGKIN LYMPHOMA DIAGNOSTIC MARKET: BY DISTRIBUTION CHANNEL, 2023-2030 (USD MILLION) 150
FIGURE 45 ASIA PACIFIC NON-HODGKIN LYMPHOMA DIAGNOSTIC MARKET: BY DISTRIBUTION CHANNEL, CAGR (2023-2030) 150
FIGURE 46 ASIA PACIFIC NON-HODGKIN LYMPHOMA DIAGNOSTIC MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE 151
FIGURE 47 ASIA-PACIFIC NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET: SNAPSHOT (2022) 156
FIGURE 48 ASIA-PACIFIC NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET: BY COUNTRY (2022) 158
FIGURE 49 ASIA-PACIFIC NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET: BY COUNTRY (2023 & 2030) 158
FIGURE 50 ASIA-PACIFIC NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET: BY COUNTRY (2022 & 2030) 159
FIGURE 51 ASIA-PACIFIC NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET: TEST TYPE (2023-2030) 160
FIGURE 52 ASIA PACIFIC NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET: COMPANY SHARE 2022 (%) 329